HELLOPRINT
6.9.2021 09:02:07 CEST | Business Wire | Press release
Helloprint, Europe’s leading online print marketplace, launches a strategic partnership with Canva, the world’s leading visual communication platform. From today, small businesses and consumers all over Europe can use Canva’s thousands of print templates and vast content library and print the designs directly via the Helloprint platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210906005030/en/
“We believe that integrating Canva’s powerful design solution and content library on our European platform is a true game-changer for us as a company and a highly desired solution by our European customers”, said Hans Scheffer, CEO of Helloprint. “The power of print lives by the quality of its designs, and Canva has democratized the way businesses and individuals can create those designs without the need of a professional designer. Adding the Canva design option to our platform will massively contribute to our mission of making ordering print easier, for everyone, everywhere.
“We’re very excited to partner up with Helloprint,” said Barry Newstead, Ecosystem and Print Lead, Canva. “We believe the power of our world-class visual communications platform combined with the strengths of Helloprint will bring a unique experience to users across Europe who want to create beautiful designs and print them in the best quality. We’ve worked hard together to provide Helloprint users the best-integrated experience possible, and we can’t wait to see it live.”
Design made simple
As the world’s fastest-growing visual communications platform, Canva provides an intuitive drag-and-drop editor, along with access to millions of free, customizable elements. Casual creatives can now design and print everything from marketing collateral to greeting cards, all with just a few clicks on the Helloprint platform. Founded in Australia in 2013, Canva is one of the fastest technology companies in the world and has over 55 million monthly active users.
About Helloprint
Helloprint is Europe’s leading online print marketplace, operating in 13 European countries and serving over 700.000 European small businesses and consumers. The huge product portfolio of over 100.000 unique products varies from promotional products to clothing, packaging, gifts, sustainable products and many more customized products. A network of hundreds of European producers is taking care of the production of the printed products, while over 30 connected carriers are taking care of the delivery, all chosen via the company’s smart technology. Helloprint has the highest standards in the market when it comes down to quality and delivery and is rated “Excellent” via its Net Promoter Score and Customer Satisfaction Score. Helloprint guarantees its customers the quality via their unique “100% Satisfaction Guarantee” and the lowest price via its “Lowest Price Guarantee”.
More info can be found on helloprint.co.uk
View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005030/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom